NCT00658580

Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer

A Phase III Randomized Study Comparing A Chemotherapy With Cisplatin And Etoposide To A Etoposide Regimen Without Cisplatin For Patients With Extensive Small-Cell Lung Cancer

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 361 (actual)
• Sponsor: European Lung Cancer Working Party · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if a cisplatin-etoposide regimen improves survival in comparison to a regimen containing etoposide and without platinum derivative.

Conditions

• Small Cell Lung Carcinoma, Extensive Disease

Interventions

Type	Name	Description
DRUG	Cisplatin + etoposide	Cisplatin 90 mg/m² day 1, every 3 weeks Etoposide 100 mg/m² days 1-3, every 3 weeks
DRUG	Epirubicin + ifosfamide + etoposide	Epirubicin 60 mg/m² day 1, every 3 weeks Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks Etoposide 100 mg/m² days 1-3, every 3 weeks

Timeline

• Start date: 2000-04-01
• Primary completion: 2013-12-01
• Completion: 2015-02-01
• First posted: 2008-04-15
• Last updated: 2015-02-12

Locations

4 sites across 4 countries: Belgium, France, Greece, Spain